MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

Home・Lista de Ações・Biogen Inc

Biogen Inc

Fechado

SetorSaúde

146.67 2.61

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

142.5

Máximo

147.35

Indicadores-chave
By Trading Economics
Rendimento	394M 635M
Vendas	215M 2.6B
P/E Médio do Setor	13.846 36.442
Margem de lucro	23.995
Funcionários	7,605
EBITDA	457M 1B

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+22.99% upside

Dividendos
By Dow Jones
Próximos Ganhos	30 de out. de 2025

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	2.3B 21B
Abertura anterior	144.06
Fecho anterior	146.67

Sentimento de Notícias

By Acuity

10%

90%

11 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

118.15 / 121.17 Suporte e Resistência

Biogen Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

20 de out. de 2025, 23:43 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Takaichi's Policy Steps -- Market Talk

20 de out. de 2025, 23:43 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

20 de out. de 2025, 23:36 UTC

Conversa de Mercado

Gold Edges Higher on Likely Dip-Buying Interest -- Market Talk

20 de out. de 2025, 22:14 UTC

Conversa de Mercado

Zions Management Confident $50M Charge Was Isolated Event -- Market Talk

20 de out. de 2025, 22:00 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Berkshire May Have Left $50 Billion on Table. Apple Stock Hit a Record. -- Barrons.com

20 de out. de 2025, 21:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Kering Sells Beauty Business to L'Oréal. Everyone but This Company Wins. -- Barrons.com

20 de out. de 2025, 20:56 UTC

Aquisições, Fusões, Aquisições de Empresas

These Stocks Moved the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20 de out. de 2025, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

20 de out. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

20 de out. de 2025, 20:38 UTC

Ganhos

Steel Dynamics: Encouraging Demand Drivers of Manufacturing Onshoring, Infrastructure Program Funding, Lower Interest Rates, Increasing Regionalization of Supply Chains in U.S. >STLD

20 de out. de 2025, 20:38 UTC

Ganhos

Steel Dynamics: Expect to Benefit From Stronger Demand Across Platforms, Including Aluminum Flat Rolled Products, as We Move Into 2026 >STLD

20 de out. de 2025, 20:38 UTC

Ganhos

Steel Dynamics: Some Order Hesitancy From Flat Rolled Steel Customers Due to Domestic Trade Actions >STLD

20 de out. de 2025, 20:36 UTC

Ganhos

Steel Dynamics: Continue to Observe Some Customer Inventory Overhang of Value-Added Flat Rolled Products That Were Imported Earlier This Yr >STLD

20 de out. de 2025, 20:36 UTC

Ganhos

Steel Dynamics: View U.S. Intl Trade Commission's Final Determinations on Coated Flat Rolled Steel as a Significant Positive Development >STLD

20 de out. de 2025, 20:36 UTC

Ganhos

Steel Dynamics: Discussions With Customers Reinforce the Increasing Importance of Low-Carbon, U.S.-Made Steel and Aluminum, Positioning Our Businesses for a Long-Term Competitive Advantage >STLD

20 de out. de 2025, 20:36 UTC

Ganhos

Steel Dynamics: Improving Market Conditions, Including Increased Trade Stability and Favorable Interest Rate Environment, Will Contribute to Strong Domestic Demand for Steel and Aluminum >STLD

20 de out. de 2025, 20:16 UTC

Conversa de Mercado

Canada Labor-Market Indicators Lean Dovish -- Market Talk

20 de out. de 2025, 20:05 UTC

Ganhos

GE Aerospace Earnings Are on Tap. After the Turnaround, Investors Wonder What's Next. -- Barrons.com

20 de out. de 2025, 19:39 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Industrials Post Positive Earnings. 3 Stocks Whose Charts Say 'Buy.' -- Barrons.com

20 de out. de 2025, 19:34 UTC

Conversa de Mercado

U.S. Natural Gas Futures Jump on Colder Weather Outlook -- Market Talk

20 de out. de 2025, 19:32 UTC

Conversa de Mercado

Oil Futures Extend Losses on Oversupply Concerns -- Market Talk

20 de out. de 2025, 19:00 UTC

Aquisições, Fusões, Aquisições de Empresas

These Stocks Are Moving the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20 de out. de 2025, 18:29 UTC

Conversa de Mercado

Apple Sitting on Best Long-Term Product Roadmap in Years -- Market Talk

20 de out. de 2025, 18:11 UTC

Conversa de Mercado

Economic Vital Signs Missing in Bank of Canada Survey -- Market Talk

20 de out. de 2025, 18:04 UTC

Conversa de Mercado

Uncertainty Remains Top Concern Among Canada Firms -- Market Talk

20 de out. de 2025, 17:03 UTC

Conversa de Mercado

Weak Demand Signals Narrower Profit Margins For Canada Firms -- Market Talk

20 de out. de 2025, 17:01 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 de out. de 2025, 17:01 UTC

Conversa de Mercado

Bank of Canada Surveys Present Shaky Economic Outlook -- Market Talk

20 de out. de 2025, 16:43 UTC

Conversa de Mercado

Canada Public-Sector Workers Fret Most On Labor-Market Weakness -- Market Talk

20 de out. de 2025, 16:25 UTC

Conversa de Mercado

U.S. Natural Gas Extends Rebound on Weather Outlook -- Market Talk

Comparação entre Pares

Variação de preço

Biogen Inc Previsão

Preço-alvo

By TipRanks

22.99% parte superior

Previsão para 12 meses

Média 175.88 USD 22.99%

Máximo 224 USD

Mínimo 118 USD

Com base em 23 analistas de Wall Street que oferecem metas de preço de 12 meses para Biogen Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

23 ratings

Comprar

Manter

Vender

Com base em 23 analistas que deram avaliações de ações para Biogen Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

118.15 / 121.17Suporte e Resistência

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimento

By Acuity

11 / 371 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.